Axa
ARQT icon

Axa’s Arcutis Biotherapeutics ARQT Stock Holding History

Axa’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-448,642
Closed -$4.28M – 1068
2023
Q2 		$4.28M Buy
448,642
+6,163
+1% +$68.4K 0.01% 589
2023
Q1 		$4.87M Buy
442,479
+106,693
+32% +$1.54M 0.02% 572
2022
Q4 		$4.97M Sell
335,786
-1,809
-0.5% -$31.6K 0.02% 600
2022
Q3 		$6.45M Buy
337,595
+113,963
+51% +$2.58M 0.03% 526
2022
Q2 		$4.77M Sell
223,632
-131,311
-37% -$2.69M 0.02% 591
2022
Q1 		$6.84M Buy
354,943
+58,690
+20% +$993K 0.02% 567
2021
Q4 		$6.14M Buy
296,253
+37,169
+14% +$740K 0.02% 613
2021
Q3 		$6.19M Buy
259,084
+15,720
+6% +$359K 0.02% 628
2021
Q2 		$6.64M Buy
243,364
+18,816
+8% +$530K 0.02% 636
2021
Q1 		$6.5M Buy
+224,548
New +$7.01M 0.02% 636

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Axa's ARQT Position: Q3 2023 in Review

Axa sold out of Arcutis Biotherapeutics (ARQT) in Q3 2023, closing a stake of 448,642 shares — an estimated $4.28M sold.

Axa first reported a position in ARQT in Q1 2021 and held it in 10 quarters. The position peaked at $6.84M in Q1 2022. 134 funds tracked by Wall St. Rank hold ARQT as of Q3 2023.

  • Axa reported no remaining Arcutis Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Axa sold 448,642 Arcutis Biotherapeutics shares in Q3 2023, an estimated $4.28M.
  • Axa first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 10 quarters.
  • Axa's Arcutis Biotherapeutics position peaked at $6.84M in Q1 2022.
  • 134 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.